Cargando…
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
Autores principales: | Locatelli, Franco, Whitlock, James A., Peters, Christina, Chen-Santel, Christiane, Chia, Victoria, Dennis, Robyn M., Heym, Kenneth M., Katz, Aaron J., Kelsh, Michael A., Sposto, Richard, Tu, Huakang, Tuglus, Catherine A., Verma, Anupam, Vinti, Luciana, Wilkes, Jennifer J., Zubarovskaja, Nathalya, Zugmaier, Gerhard, von Stackelberg, Arend, Sun, Weili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449874/ https://www.ncbi.nlm.nih.gov/pubmed/32094465 http://dx.doi.org/10.1038/s41375-020-0770-8 |
Ejemplares similares
-
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: Gore, Lia, et al.
Publicado: (2018) -
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
por: Mejstríková, E., et al.
Publicado: (2017) -
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
por: Locatelli, Franco, et al.
Publicado: (2020) -
Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
por: Locatelli, Franco, et al.
Publicado: (2021) -
Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia
por: Gökbuget, Nicola, et al.
Publicado: (2020)